Dr. Reddy’s Laboratories share price fell in the early trade on July 21 following USFDA issued observations to the company's manufacturing facility in Srikakulam, Andhra Pradesh post an inspection.
At 09:27am, Dr Reddy's Laboratories was quoting at Rs 1,250.35, down Rs 7.75, or 0.62 percent, on the BSE.
"The United States Food & Drug Administration (USFDA) completed a GMP and a pre-approval inspection (PAI) at formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh, India," company said in its release.
The inspection was conducted from July 10 to 18, 2025.
Catch all the market action on our live blog
The company received a Form 483 with 7 observations, which it will address within the stipulated timeline.
The company is going to announce results for the quarter ended June 30th, 2025 on July 23, 2025 after the board meeting.
The share touched a 52-week high of Rs 1,420.20 and a 52-week low of Rs 1,025.90 on 21 August, 2024 and 07 April, 2025, respectively.
Currently, the stock is trading 11.96 percent below its 52-week high and 21.88 percent above its 52-week low.
The market capitalisation of the company stands at Rs 104,351.93 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
